Medicine Recommendations

Osteoarthritis

Psoriasis

Acute Gout (as per LSCMMG Guidelines)

For replacement therapy of adrenal insufficiency in children and adolescents (from birth to <18 years old)

Treatment of congenital adrenal hyperplasia (CAH) in adolescents aged 12 years and over and adults.

Treatment of adrenal insufficiency in adults.

Treatment of mild non-infectious allergic or inflammatory conjunctival diseases

Treatment of essential thrombocythemia or polycythaemia vera with a high risk for thromboembolic complications

Psoriasis

The prevention of recurrent painful vaso-occlusive crises including acute chest syndrome in adults suffering from symptomatic Sickle Cell Syndrome

Rheumatoid conditions, lupus erythematosus, dermatological conditions

Bowel obstruction - colic associated with bowel obstruction AND GI secretions associated with bowel obstruction

Respiratory tract secretions in the last days of life

Hypersalivation

The colour classification was determined as part of the collaborative work between LCFT and Medicines Management leads. Local pathways and patient safety were taken into consideration.

Respiratory tract secretions in the last days of life

Treatment of post menopausal osteoporosis

MHRA Drug Safety Update - Bisphosphonates: very rare reports of osteonecrosis of the external auditory canal

MHRA Drug Safety Update - Bisphosphonates: atypical femoral fractures

Postmenopausal osteoporosis

MHRA Drug Safety Update - Bisphosphonates: very rare reports of osteonecrosis of the external auditory canal

MHRA Drug Safety Update - Bisphosphonates: atypical femoral fractures

adjuvant treatment of early breast cancer in postmenopausal women with a high risk of recurrence (unlicensed indication)

Acute Gout (as per LSCMMG Guidelines)

MHRA Drug Safety Update - High-dose ibuprofen (≥2400mg/day): small increase in cardiovascular risk

MHRA Drug Safety Update - Non-steroidal anti-inflammatory drugs (NSAIDs): reminder on renal failure and impairment

MHRA Drug Safety Update - Non-steroidal anti-inflammatory drugs (NSAIDs): cardiovascular risks

MHRA Drug Safety Update - NSAIDs and coxibs: balancing of cardiovascular and gastrointestinal risks

Pain

MHRA Drug Safety Update - High-dose ibuprofen (≥2400mg/day): small increase in cardiovascular risk

MHRA Drug Safety Update - Non-steroidal anti-inflammatory drugs (NSAIDs): reminder on renal failure and impairment

MHRA Drug Safety Update - Non-steroidal anti-inflammatory drugs (NSAIDs): cardiovascular risks

MHRA Drug Safety Update - NSAIDs and coxibs: balancing of cardiovascular and gastrointestinal risks

Pain: Anti-inflammatory